The FDA approved the first GLP-1 agonist, exenatide, to treat type 2 diabetes in 2005
Among firms offering family coverage, 38% of covered workers in small firms are enrolled in a plan with a premium contribution exceeding $10,000, compared to 12% of covered workers in large firms
By Dana G
What do we know about their safety and efficacy
Explaining how some GLP-1 drugs can cause a loss in muscle mass, Andy explained, "I am on a pretty rigorous health journey with Stani, who is like, 'OK, if you're going to do this,' he put me on way heavier weights. "And, by the way, I should mention, I feel privileged to have access to a GLP-1, and I think everybody should, through insurance," he continued